1. Home
  2. MESO vs SBLK Comparison

MESO vs SBLK Comparison

Compare MESO & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • SBLK
  • Stock Information
  • Founded
  • MESO 2004
  • SBLK 2006
  • Country
  • MESO Australia
  • SBLK Greece
  • Employees
  • MESO N/A
  • SBLK N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • SBLK Marine Transportation
  • Sector
  • MESO Health Care
  • SBLK Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • SBLK Nasdaq
  • Market Cap
  • MESO 1.8B
  • SBLK 2.1B
  • IPO Year
  • MESO N/A
  • SBLK N/A
  • Fundamental
  • Price
  • MESO $16.02
  • SBLK $19.83
  • Analyst Decision
  • MESO Strong Buy
  • SBLK Strong Buy
  • Analyst Count
  • MESO 2
  • SBLK 1
  • Target Price
  • MESO $24.00
  • SBLK $22.00
  • AVG Volume (30 Days)
  • MESO 159.9K
  • SBLK 969.8K
  • Earning Date
  • MESO 08-28-2025
  • SBLK 11-18-2025
  • Dividend Yield
  • MESO N/A
  • SBLK 1.01%
  • EPS Growth
  • MESO N/A
  • SBLK N/A
  • EPS
  • MESO N/A
  • SBLK 0.53
  • Revenue
  • MESO $17,198,000.00
  • SBLK $1,050,829,000.00
  • Revenue This Year
  • MESO $440.77
  • SBLK N/A
  • Revenue Next Year
  • MESO $110.74
  • SBLK $19.06
  • P/E Ratio
  • MESO N/A
  • SBLK $37.61
  • Revenue Growth
  • MESO 191.39
  • SBLK N/A
  • 52 Week Low
  • MESO $9.61
  • SBLK $12.06
  • 52 Week High
  • MESO $22.00
  • SBLK $19.99
  • Technical
  • Relative Strength Index (RSI)
  • MESO 52.88
  • SBLK 65.01
  • Support Level
  • MESO $14.32
  • SBLK $18.74
  • Resistance Level
  • MESO $15.61
  • SBLK $19.61
  • Average True Range (ATR)
  • MESO 0.57
  • SBLK 0.49
  • MACD
  • MESO 0.11
  • SBLK 0.11
  • Stochastic Oscillator
  • MESO 87.78
  • SBLK 98.50

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

About SBLK Star Bulk Carriers Corp.

Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.

Share on Social Networks: